Iodine i 131 apamistamab is under clinical development by Actinium Pharmaceuticals and currently in Phase III for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase III drugs for Relapsed Acute Myeloid Leukemia have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Iodine i 131 apamistamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Iodine i 131 apamistamab overview
Iomab-B, a radioimmunoconjugate (BC8-I-131 construct) is under development for the treatment of relapsed and refractory follicular lymphoma, chronic lymphocytic leukemia, high-grade B-cell lymphoma, diffuse large B-cell lymphoma, relapsed and refractory B-cell acute lymphoblastic leukemia and chronic myeloid leukemia (CML), acute myelocytic leukemia (AML), acute lymphoblastic leukemia, relapsed and/or refractory elderly acute myeloid leukemia, chronic myelomonocytic leukemia, sickle cell disease, multiple myeloma and refractory anemia with ringed sideroblasts and for prevention of lymphodepletion during CAR-T therapy. It is administered parenterally through intravenous route. The drug is a radionuclide drug conjugate (RDC) which consists of monoclonal antibody apamistamab and the beta emitting radioisotope I131 (I-131). It acts by targeting CD45 and is developed by using Alpha Particle Immunotherapy, Antibody Warhead Enabling (AWE) Technology platform. It was also under development for Hodgkin lymphoma, relapsed/refractory B-non-Hodgkin lymphoma (B-NHL), T-non-Hodgkin lymphoma(T-NHL) and mantle cell lymphoma.
It was also under development for Myelodysplastic Syndrome, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts, Leukemia, Myeloproliferative Disorders and cytopenia.
Actinium Pharmaceuticals overview
Actinium Pharmaceuticals (Actinium) is a biopharmaceutical company focused on developing targeted radiotherAPIes for cancer patients with limited treatment options. The company’s pipeline products include Iomab-B (CD45) for depleting blood cancer, immune and bone marrow stem cells; Iomab-ACT (CD45) for treating GeneTx and Cell therapy conditioning; Actimab-A(CD33) for treating relapsed/refractory AML; Actimab-A (CD33) and CLAG-M; Actimab-A (CD33) and Venetoclax and Actimab-A (CD33) and Venetoclax with HMA. It uses proprietary technology platforms to create antibody radiation conjugates (ARCs) for targeted radiotherapy. The company collaborates with research institutions. ATNM is headquartered in New York City, New York, the US.
For a complete picture of Iodine i 131 apamistamab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
